The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Skin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Self-citation
Cited by
Peris, K., Fargnoli, M. C., Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113254 · Cited by 308
Self-citationHaensel, D., Daniel, B., Gaddam, S., Pan, C., Fabo, T., Bjelajac, J., Jussila, A. R., Gonzalez, F., Li, N. Y., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37993-w · Cited by 29
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
Yue, M., Li, C., & Li, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111799 · Cited by 12
Metadata
- Authors
- Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Prey, S., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. L. S., Dalle, S., Orland, A. F., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M. R., Dummer, R., Li, S., Yoo, S.-Y., Mohan, K., Coates, E., Jankovic, V., Fiaschi, N., Okoye, E., Bassukas, I. D., Loquai, C., De Giorgi, V., Eroglu, Z., Gutzmer, R., Ulrich, J., Puig, S., Seebach, F., Thurston, G., Weinreich, D. M., Yancopoulos, G. D., Lowy, I., Bowler, T., & Fury, M. G.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 22
- Issue
- 6
- Pages
- 848-857
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3160231856
- Cited by
- 286
- References
- 6
- FWCI
- 32.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00126-1
- The paper
- Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Prey, S., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. L. S., Dalle, S., Orland, A. F., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M. R., Dummer, R., Li, S., Yoo, S.-Y., . . . Fury, M. G. (2021). Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00126-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
